World Class Drug Hunters + Capital Efficient Progress = Founders Win That's Curie.Bio. We bring the most exciting therapeutic ideas to clinical proof of concept in just two financing rounds, meaning founders own more of their company at the end. We do that through a unique combination of investing and drug discovery copiloting in early-stage therapeutics companies. We share more about what we're all about below.
Curie.Bio’s Post
More Relevant Posts
-
Excited to have Arkesh Mehta, Chairman & CEO of OncoBindi, Inc., at Day 2 of the Alcor Drug Discovery Platform! Join us for a compelling presentation on the NanoBindi-Platform for accelerated Therapeutics Development. Don't miss this opportunity to explore groundbreaking advancements in drug discovery! #AlcorDrugDiscovery #NanoBindi #TherapeuticsDevelopment #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits
-
-
What’s in Store for 2024? Three CEOs Look Ahead and Look Back on “Close to the Edge” https://ow.ly/WPPZ50Qmb8E From the approval of Alzheimer’s disease drug Leqembi to Carl Icahn’s battle over Illumina to the first CRISPR-edited therapy being approved, 2023 had more than its share of milestones shaping drug discovery, development, clinical trials, and commercialization. To look back at the year that is ending, and look ahead to 2024, GEN invited CEOs of three companies to offer some valuable perspective on the biopharma industry’s strengths and challenges, and the strengths and challenges of their own companies. • Neil McFarlane, CEO of Zevra Therapeutics • Karen Zaderej, CEO of axogen • Simon Arkell OLY, CEO of Ryght
-
-
Source. Plan. Invest. Execute. These sound like simple directions, but in the context of pre-seed therapeutics investment the route can be hard to navigate. In the next chapter of Evotec’s White Paper series, ‘From academic concept to commercial reality: How to accelerate translational drug discovery’ we take a look from an investor’s perspective at the way-markers for a successful translational roadmap. Read chapter 2, 'Source. Plan. Invest. Execute. Navigating the tough roadmap of pre-seed therapeutics investment' here - https://hubs.ly/Q02j-Bfx0 #researchneverstops
-
-
Science marketing & communication 🧬 scaling up your content production 🧬 2-time founder (1 exit, 1 active)
Boston is considered by many to be the capital of the #biotech world. But who are the top rising biotechs right now? 🔥 Here are the top 6, ranked by amount raised in the last 2 years: 6. Cellarity: October 2022 - series C - $121 million 5. MOMA Therapeutics: May 2022 - series B - $150 million 4. Orna Therapeutics: August 2022 - series B - $221 million 3. Neumora Therapeutics: October 2022 - series B - $112 million + September 2023 - IPO $250 million 2. Tessera Therapeutics: April 2022 - series C - $300 million 1. ElevateBio: May 2023 - series D - $401 million Labiotech.eu has a list including 6 more companies to watch in the Boston area (link in comments). .................................. #boston #drugdevelopment
-
Check out Optimum's latest podcast featuring an expert panel discussing the issue of diversity in clinical trial recruitment. Thanks to Germo Gericke, Annalisa Jenkins and John Maher for taking part!
Diverse recruitment for #clinicaltrials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum Strategic Communications’ Richard Staines as he discuses this thorny issue with Ariceum Therapeutics CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Thought Leader Annalisa Jenkins. 📢 Listen to the latest episode of the #OptimumPerspectivesPodcast now: https://lnkd.in/eEwyCix9 #Ariceum #Leucidbio
-
Listen to Optimum Strategic Communications latest podcast around #clinicaltrials
Diverse recruitment for #clinicaltrials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum Strategic Communications’ Richard Staines as he discuses this thorny issue with Ariceum Therapeutics CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Thought Leader Annalisa Jenkins. 📢 Listen to the latest episode of the #OptimumPerspectivesPodcast now: https://lnkd.in/eEwyCix9 #Ariceum #Leucidbio
-
IRLAB Therapeutics AB In our recent analysis conducted with EQL desktop, we have reviewed IRLAB Therapeutics AB, a biopharmaceutical company based in Gothenburg, Sweden. Current Developments: IRLAB's development pipeline includes Mesdopetam in phase IIb/III trials for dyskinesia in Parkinson’s disease and several preclinical initiatives aimed at neurodegenerative disorders. Strategic Approach: Our research provides an objective look into IRLAB’s strategic methods and the progress of their clinical trials, presenting a clear picture of their operations and potential implications for patient care. Sign up today: https://lnkd.in/dJ8zhDrP #ResearchwithAI #EQL #Irlab #marketintelligence
-
-
Join our leaders at #jpm2024 and learn more about the work Eikon Therapeutics is focused on across the intersection of Science and Technology. #biotech #biotechcareers
Thrilled to have a prime speaking slot at JPM! Look forward to meeting with the many investors, potential partners interested in the Eikon Therapeutics story and catching up with old friends. DM if interested in connecting with Eikon Therapeutics as we advanced a meaninfully derisked clinical portfolio. #jpm24
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical
Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials
https://endpts.com
Operate at the intersection of business and science | aMoon | Biotech Executive | Ex-BCG
2mosuper video, well done!!!!!!!